Although the effects of c-Met inhibition have been reported in different cancer types, no other studies have explored the potential therapeutic effect(s) of a combination treatment with a c-Met inhibitor and an inhibitor of its downstream effector HO-1 on renal cancer growth. This evidence concerns the gene HMOX1 and renal carcinoma.